Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Sintanovo

    • Home
    • Sintanovo
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo...

Recent updates

  • Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development
  • CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included
  • ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
  • Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin
  • NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.